

Keunchil Park

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4716019/keunchil-park-publications-by-year.pdf>

Version: 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

522
papers

29,311
citations

74
h-index

160
g-index

578
ext. papers

36,487
ext. citations

5
avg, IF

6.73
L-index

#	Paper	IF	Citations
522	ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer.. <i>Investigational New Drugs</i> , 2022 , 40, 265	4.3	0
521	Dynamics of circulating immune cells during chemoradiotherapy in patients with non-small cell lung cancer support earlier administration of anti-PD-1/PD-L1 therapy.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022 ,	4	1
520	Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.. <i>Oncology</i> , 2022 , 1-10	3.6	
519	Hypersensitivity Reactions to Selpercatinib Treatment with or Without Prior Immune Checkpoint Inhibitor Therapy in Patients with Non-Small-Cell Lung Cancer in LIBRETTO-001.. <i>Journal of Thoracic Oncology</i> , 2022 ,	8.9	2
518	Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.. <i>Current Oncology</i> , 2022 , 29, 2154-2164	2.8	0
517	Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102010	2.2	4
516	ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer.. <i>Lancet Oncology, The</i> , 2022 , 23, 463-464	21.7	0
515	Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon Mutations: An Updated Database of 1023 Cases Brief Report.. <i>Frontiers in Oncology</i> , 2022 , 12, 834704	5.3	1
514	Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience. <i>European Journal of Cancer</i> , 2021 , 159, 167-173	7.5	2
513	Tepotinib Efficacy and Safety in Patients with Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. <i>Clinical Cancer Research</i> , 2021 ,	12.9	5
512	Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment.. <i>Translational Lung Cancer Research</i> , 2021 , 10, 4209-4220	4.4	0
511	Real-time automatically updated data warehouse in healthcare (ROOT): an innovative and automated data collection system. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3865-3874	4.4	
510	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	18
509	Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. <i>International Journal of Clinical Oncology</i> , 2021 , 26, 841-850	4.2	1
508	Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer. <i>Korean Journal of Internal Medicine</i> , 2021 , 36, S217-S224	2.5	3
507	Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. <i>Journal of Korean Neurosurgical Society</i> , 2021 , 64, 271-281	2.3	4
506	Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1349-1359	2.2	37

505	Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial. <i>Lung Cancer</i> , 2021 , 154, 92-98	5.9	2
504	High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. <i>Cancer</i> , 2021 , 127, 3019-3028	6.4	6
503	KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8512-8512	2.2	3
502	Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9065-9065	2.2	2
501	A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor (KCSG LU17-21).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8576-8576	2.2	1
500	Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. <i>Lung Cancer</i> , 2021 , 155, 127-135	5.9	2
499	Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion+ non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9032-9032	2.2	0
498	The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8562-8562	2.2	0
497	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. <i>Clinical Lung Cancer</i> , 2021 ,	4.9	2
496	The NHance Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients. <i>Biomedicines</i> , 2021 , 9,	4.8	2
495	Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience. <i>European Journal of Endocrinology</i> , 2021 , 184, 837-845	6.5	4
494	Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC). <i>Clinical Lung Cancer</i> , 2021 , 22, 549-561	4.9	4
493	EGFR tyrosine kinase inhibitors for mutation-positive non-small-cell lung cancer: outcomes in Asian populations. <i>Future Oncology</i> , 2021 , 17, 2395-2408	3.6	5
492	Intracranial Efficacy of Selpercatinib in Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 4160-4167	12.9	12
491	An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations. <i>BMC Cancer</i> , 2021 , 21, 802	4.8	1
490	Abstract CT163: CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study 2021 ,		2
489	Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥10%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2327-2338	2.2	53
488	RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	5

487	Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. <i>Frontiers in Oncology</i> , 2021 , 11, 709877	5.3	1
486	Phase III study of selipercatinib versus chemotherapy plus pembrolizumab in untreated positive non-small-cell lung cancer. <i>Future Oncology</i> , 2021 , 17, 763-773	3.6	13
485	Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive -mutant Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 992-1002	12.9	17
484	Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 140-150	8.9	32
483	Olmotinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study. <i>Cancer</i> , 2021 , 127, 1407-1416	6.4	8
482	Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study. <i>Annals of Palliative Medicine</i> , 2021 , 10, 1589-1598	1.7	1
481	Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors. <i>Translational Lung Cancer Research</i> , 2021 , 10, 878-888	4.4	3
480	Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. <i>European Journal of Immunology</i> , 2021 , 51, 956-964	6.1	4
479	Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3391-3402	2.2	62
478	Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1369-1378	8.9	5
477	Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100206	1.4	1
476	Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. <i>JAMA Oncology</i> , 2021 ,	13.4	26
475	Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021 , 37, 102415	6	5
474	Regulatory (FoxP3) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2020 , 10, 18994	4.9	17
473	Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With Exon 14 Skipping. <i>In Vivo</i> , 2020 , 34, 1399-1406	2.3	4
472	Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. <i>Nature Communications</i> , 2020 , 11, 2285	17.4	163
471	Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma. <i>European Journal of Cancer</i> , 2020 , 132, 150-158	7.5	14
470	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 1133-1143	35.1	66

469	Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. <i>Lung Cancer</i> , 2020 , 146, 23-29	5.9	28
468	Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery. <i>Journal of Thoracic Disease</i> , 2020 , 12, 2602-2613	2.6	3
467	MDSC subtypes and CD39 expression on CD8 T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. <i>European Journal of Immunology</i> , 2020 , 50, 1810-1819	6.1	16
466	Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime automatically updated data warehouse in health care; UNIVERSE-ROOT study). <i>Lung Cancer</i> , 2020 , 146, 112-119	5.9	3
465	Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. <i>Cancer</i> , 2020 , 126, 2704-2712	6.4	14
464	Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. <i>Cancer</i> , 2020 , 126, 4002-4012	6.4	4
463	PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. <i>Cancer Medicine</i> , 2020 , 9, 2352-2362	4.8	14
462	Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study. <i>Targeted Oncology</i> , 2020 , 15, 75-84	5	5
461	Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. <i>Nature Communications</i> , 2020 , 11, 951	17.4	14
460	Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. <i>Onc Immunology</i> , 2020 , 9, 1722023	7.2	13
459	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 520-540	8.9	42
458	Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice. <i>Japanese Journal of Clinical Oncology</i> , 2020 , 50, 594-601	2.8	6
457	Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 803-815	8.9	77
456	Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. <i>BMC Ophthalmology</i> , 2020 , 20, 19	2.3	16
455	Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer. <i>Respiratory Research</i> , 2020 , 21, 13	7.3	4
454	Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. <i>Nature</i> , 2020 , 578, 102-111	50.4	220
453	Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020 , 122, 1630-1637	8.7	190
452	CTNI-04. ACTIVITY OF LAROTRECTINIB IN TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES. <i>Neuro-Oncology</i> , 2020 , 22, ii41-ii42	1	1

451	Selpercatinib (LOXO-292) in patients with RET-fusion+ non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3584-3584	2.2	10
450	Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9512-9512	2.2	41
449	Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9516-9516	2.2	12
448	Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea. <i>Cancer Research and Treatment</i> , 2020 , 52, 292-300	5.2	8
447	EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation. <i>Cancer Research and Treatment</i> , 2020 , 52, 1288-1290	5.2	4
446	Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs. <i>Immune Network</i> , 2020 , 20, e48	6.1	1
445	Comprehensive molecular characterization of mitochondrial genomes in human cancers. <i>Nature Genetics</i> , 2020 , 52, 342-352	36.3	105
444	Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review. <i>Head and Neck</i> , 2020 , 42, 924-938	4.2	7
443	Junction Location Identifier (JuLI): Accurate Detection of DNA Fusions in Clinical Sequencing for Precision Oncology. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 304-318	5.1	1
442	Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). <i>Journal of Clinical Oncology</i> , 2020 , 38, 488-495	2.2	121
441	Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. <i>Clinical Lung Cancer</i> , 2020 , 21, e182-e190	4.9	3
440	Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 609-617	8.9	15
439	Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY. <i>Cancer Science</i> , 2020 , 111, 4510-4525	6.9	8
438	Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity 2020 , 8,		2
437	Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon Mutations: Are They Different from Those with Common Mutations?. <i>Biology</i> , 2020 , 9,	4.9	3
436	Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. <i>Lung Cancer</i> , 2020 , 147, 137-142	5.9	13
435	The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1749-1758	4.4	4
434	A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. <i>Frontiers in Oncology</i> , 2020 , 10, 578756	5.3	17

433	Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. <i>Scientific Reports</i> , 2020 , 10, 13231	4.9	5
432	Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. <i>BMC Cancer</i> , 2020 , 20, 727	4.8	6
431	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920926796	5.4	5
430	Evaluating entrectinib as a treatment option for non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1935-1942	4	5
429	Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1758-1766	8.9	28
428	KRAS Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020 , 383, 1207-1217	59.2	469
427	Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 813-824	59.2	194
426	Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation. <i>European Journal of Cardio-thoracic Surgery</i> , 2020 , 58, 1019-1026	3	
425	Integrative genomic analysis of salivary duct carcinoma. <i>Scientific Reports</i> , 2020 , 10, 14995	4.9	4
424	Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?. <i>Journal of Thoracic Disease</i> , 2020 , 12, 3796-3803	2.6	6
423	Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). <i>European Journal of Cancer</i> , 2020 , 137, 272-284	7.5	32
422	Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. <i>Investigational New Drugs</i> , 2020 , 38, 360-368	4.3	15
421	Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis. <i>Current Medical Research and Opinion</i> , 2020 , 36, 477-482	2.5	4
420	Predictive and Prognostic Value of F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2019 , 9, 12215	4.9	0
419	Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. <i>European Journal of Cancer</i> , 2019 , 120, 65-74	7.5	16
418	DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. <i>Nature Communications</i> , 2019 , 10, 4278	17.4	109
417	Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 2020-2031	59.2	960
416	Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery. <i>Radiotherapy and Oncology</i> , 2019 , 133, 87-92	5.3	10

415	Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients. <i>Clinical Lung Cancer</i> , 2019 , 20, e309-e318	4.9	8
414	Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 193-202	8.9	59
413	Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. <i>Clinical Lung Cancer</i> , 2019 , 20, 215-221	4.9	8
412	Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. <i>Lung Cancer</i> , 2019 , 134, 7-15	5.9	21
411	Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma 2019 , 7, 128		13
410	Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1255-1265	8.9	36
409	First-line afatinib for the treatment of mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919836374	5.4	20
408	Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 1341-1349	4.9	13
407	Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study. <i>Anticancer Research</i> , 2019 , 39, 1403-1409	2.3	5
406	Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2162-2170	2.2	101
405	First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. <i>Lung Cancer</i> , 2019 , 133, 10-19	5.9	14
404	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019 , 132, 126-131	5.9	17
403	Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. <i>Lung Cancer</i> , 2019 , 130, 87-92	5.9	25
402	Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. <i>International Journal of Cancer</i> , 2019 , 145, 2433-2439	7.5	11
401	Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 446-454	8.8	40
400	Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. <i>Cancer Research and Treatment</i> , 2019 , 51, 502-509	5.2	45
399	DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1640-1650	8.9	36
398	Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. <i>Lung Cancer</i> , 2019 , 135, 66-72	5.9	18

397	Nivolumab + chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722). <i>Annals of Oncology</i> , 2019 , 30, vi126	10.3	5
396	Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1608-1618	8.9	47
395	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 1655-1669	21.7	215
394	Abstract CT193: Tepotinib + gefitinib vs chemotherapy in MET-amplified EGFR-mutant non-small cell lung cancer (NSCLC): Predefined subgroup analysis of a Phase Ib/II study 2019 ,		2
393	Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8514-8514	2.2	6
392	Phase II, prospective single-arm study of adjuvant pembrolizumab in N2 positive non-small cell lung cancer (NSCLC) treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection: Preliminary results.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8520-8520	2.2	2
391	JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9009-9009	2.2	50
390	Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9094-9094	2.2	1
389	Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III non-small-cell lung cancer (NSCLC): KEYNOTE-799.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS8575-TPS8575	2.2	1
388	Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 387-387	2.2	51
387	Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Korean Journal of Internal Medicine</i> , 2019 , 34, 1107-1115	2.5	1
386	Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019 , 51, 119-127	5.2	18
385	EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. <i>Cancer Research and Treatment</i> , 2019 , 51, 493-501	5.2	13
384	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019 , 51, 211-222	5.2	5
383	Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019 , 51, 408-412	5.2	11
382	Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2019 , 51, 623-631	5.2	22
381	A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. <i>Cancer Research and Treatment</i> , 2019 , 51, 718-726	5.2	6
380	Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019 , 51, 769-776	5.2	6

379	Severe immune-related adverse events in anti-PD-1-treated patients are clustered into distinct subtypes by peripheral blood T-cell profiles.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2564-2564	2.2	
378	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 1569-1579	4.9	24
377	Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. <i>Future Oncology</i> , 2019 , 15, 1363-1383	3.6	8
376	The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel with and Without Anti-angiogenic Agent in Advanced Non-small Cell Lung Cancer After Progression on	0.1	
375	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019 , 24, 1095-1102	5.7	16
374	In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e279-e280	8.9	
373	Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing. <i>PLoS ONE</i> , 2019 , 14, e0224379	3.7	9
372	Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. <i>Lung Cancer</i> , 2019 , 128, 105-112	5.9	77
371	Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: FDG Uptake and Risk Stratification. <i>Clinical Nuclear Medicine</i> , 2019 , 44, e60-e67	1.7	1
370	The First-week Proliferative Response of Peripheral Blood PD-1CD8 T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 2144-2154	12.9	74
369	Imaging genotyping of functional signaling pathways in lung squamous cell carcinoma using a radiomics approach. <i>Scientific Reports</i> , 2018 , 8, 3284	4.9	9
368	Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e34-e36	8.9	18
367	Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy. <i>Lung Cancer</i> , 2018 , 117, 7-13	5.9	8
366	Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). <i>British Journal of Cancer</i> , 2018 , 118, 648-653	8.7	13
365	Phase 1b Trial of Ficlaturuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. <i>Clinical Pharmacology in Drug Development</i> , 2018 , 7, 532-542	2.3	15
364	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 576-584	8.9	45
363	KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e29-e31	8.9	16
362	Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 106-111	8.9	130

361	Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. <i>Lung Cancer</i> , 2018 , 119, 36-41	5.9	5
360	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. <i>Clinical Lung Cancer</i> , 2018 , 19, e465-e479	4.9	39
359	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2018 , 19, 521-536	21.7	315
358	A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018 , 19, 27-34	4.9	17
357	Clinical Presentation and Prognostic Factors in Lung Cancer 2018 , 186-198.e6		
356	Low-power and low-drug-dose photodynamic chemotherapy via the breakdown of tumor-targeted micelles by reactive oxygen species. <i>Journal of Controlled Release</i> , 2018 , 286, 240-253	11.7	14
355	Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial. <i>Lung Cancer</i> , 2018 , 124, 293-297	5.9	10
354	Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2018 , 122, 160-164	5.9	5
353	Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1373-1382	8.9	57
352	Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1106-1112	8.9	23
351	Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. <i>Cancer Science</i> , 2018 , 109, 2852-2862	6.9	9
350	A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 102-102	2.2	72
349	A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9025-9025	2.2	20
348	Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9048-9048	2.2	3
347	An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9050-9050	2.2	11
346	Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9053-9053	2.2	3
345	Durvalumab in 1 st -line advanced NSCLC: Updated results from the phase 2 ATLANTIC study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9058-9058	2.2	3
344	Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9075-9075	2.2	18

343	An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS3120-TPS3120	2.2	4
342	Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). <i>Journal of Pathology and Translational Medicine</i> , 2018 , 52, 148-156	2.9	11
341	Clinical outcomes of EGFR exon 20 insertion in advanced NSCLC in Korea.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21136-e21136	2.2	
340	Monitoring peripheral blood PD-1+CD8+T cells to predict response to anti-PD-1 therapy in solid tumors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24115-e24115	2.2	
339	Integrative whole-genome analysis of salivary duct carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6083-6083	2.2	
338	Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer. <i>Lung Cancer</i> , 2018 , 115, 89-96	5.9	15
337	Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion. <i>Radiation Oncology</i> , 2018 , 13, 245	4.2	1
336	Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , 2018 , 19, 1468-1479	21.7	237
335	Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. <i>Lung Cancer</i> , 2018 , 126, 1-8	5.9	28
334	Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1906-1918	8.9	50
333	Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1156-1170	8.9	134
332	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. <i>Lung Cancer</i> , 2018 , 122, 234-242	5.9	15
331	Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model. <i>PLoS ONE</i> , 2018 , 13, e0194730	3.7	14
330	Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). <i>Cancer</i> , 2017 , 123, 1958-1964	6.4	28
329	Osimertinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 225-231	4	2
328	EGFR TKI combination with immunotherapy in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 465-469	4.1	104
327	Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017 , 13, e239-e245	1.9	6
326	Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2017 , 112, 126-133	5.9	7

325	P3.02b-005 Phase Ib Trial of Afatinib and BI 836845 in Advanced NSCLC: Dose Escalation and Safety Results. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1187-S1188	8.9	2
324	Prospects and progress of atezolizumab in non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 781-789	5.4	11
323	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <i>Lancet, The</i> , 2017 , 389, 255-265	4.0	2681
322	A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2017 , 122, 217-223	5.3	
321	Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?. <i>Cancer Treatment Reviews</i> , 2017 , 61, 70-81	14.4	46
320	Lipiodol nanoemulsions stabilized with polyglycerol-polycaprolactone block copolymers for theranostic applications. <i>Biomaterials Research</i> , 2017 , 21, 21	16.8	8
319	Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3065-3074	2.2	229
318	Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3662-3670	2.2	18
317	Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. <i>JCO Precision Oncology</i> , 2017 , 1,	3.6	18
316	Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. <i>Oncolmunology</i> , 2017 , 7, e1375642	7.2	52
315	An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 933-942	3.8	3
314	ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1357-1367	8.9	100
313	Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 591-598	3.5	34
312	Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?. <i>Current Opinion in Oncology</i> , 2017 , 29, 89-96	4.2	12
311	Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer. <i>British Journal of Cancer</i> , 2017 , 117, 757-766	8.7	18
310	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. <i>Nature Communications</i> , 2017 , 8, 1377	17.4	92
309	Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1806-1813	8.9	16
308	Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer. <i>Cancer Research and Treatment</i> , 2017 , 49, 906-914	5.2	15

307	A phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8521-8521	2.2	13
306	Phase Ib study of tepotinib in EGFR-mutant/c-Met-positive NSCLC: Final data and long-term responders.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8547-8547	2.2	1
305	Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9001-9001	2.2	14
304	Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery. <i>Oncotarget</i> , 2017 , 8, 3542-3552	3.3	6
303	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. <i>Oncotarget</i> , 2017 , 8, 3237-3245	3.3	13
302	Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences. <i>Oncotarget</i> , 2017 , 8, 42478-42486	3.3	16
301	Mutational status of defines the efficacy of Wee1 inhibitor AZD1775 in -mutant non-small cell lung cancer. <i>Oncotarget</i> , 2017 , 8, 67526-67537	3.3	10
300	NTRK gene amplification in patients with metastatic cancer. <i>Precision and Future Medicine</i> , 2017 , 1, 129-137		9
299	A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2017 , 49, 816-823	5.2	8
298	Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study. <i>Cancer Research and Treatment</i> , 2017 , 49, 937-946	5.2	7
297	Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 92-92	2.2	
296	The feasibility of using small biopsy samples from lung cancer for targeted next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20584-e20584	2.2	1
295	Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience. <i>Cancer Research and Treatment</i> , 2017 , 49, 880-889	5.2	0
294	LUX-Lung 7: is there enough data for a final conclusion? - Author's reply. <i>Lancet Oncology</i> , 2016 , 17, e268-e269	21.7	
293	Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. <i>Medical Oncology</i> , 2016 , 33, 97	3.7	30
292	Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor. <i>Lung Cancer</i> , 2016 , 100, 24-29	5.9	3
291	MINI01.01: Whole Body and Intracranial Efficacy of Crizotinib in ALK-inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3. <i>Journal of Thoracic Oncology</i> , 2016 , 11, S256	8.9	10
290	Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study. <i>Lung Cancer</i> , 2016 , 98, 9-14	5.9	24

289	Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study. <i>Cancer Imaging</i> , 2016 , 16, 5	5.6	19
288	Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. <i>Investigational New Drugs</i> , 2016 , 34, 625-35	4.3	42
287	Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e1-4	8.9	59
286	Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. <i>Lung Cancer</i> , 2016 , 93, 95-103	5.9	34
285	Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e45-7	8.9	82
284	Pembrolizumab for the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 397-406	5.4	52
283	Reply to Y.H. Kim and M. Mishima. <i>Journal of Clinical Oncology</i> , 2016 , 34, 768	2.2	
282	Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016 , 46, 40-5	2.8	7
281	First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 370-9	8.9	11
280	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 453-74	8.9	106
279	Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 1837-46 ⁰	46 ⁰	173 ¹
278	First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. <i>JAMA Oncology</i> , 2016 , 2, 305-12	13.4	164
277	Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). <i>Clinical Cancer Research</i> , 2016 , 22, 2386-95	12.9	138
276	Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). <i>Radiotherapy and Oncology</i> , 2016 , 118, 244-50	5.3	27
275	A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. <i>Clinical Cancer Research</i> , 2016 , 22, 2139-45	12.9	25
274	Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. <i>Supportive Care in Cancer</i> , 2016 , 24, 301-309	3.9	10
273	Highly dense, optically inactive silica microbeads for the isolation and identification of circulating tumor cells. <i>Biomaterials</i> , 2016 , 75, 271-278	15.6	21
272	Cell-free DNA sequencing-guided therapy in a prospective clinical trial: NEXT-2 trial feasibility analysis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11534-11534	2.2	2

271	MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2508-2508	2.2	15
270	Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6090-6090	2.2	1
269	A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9013-9013	2.2	11
268	Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9028-9028	2.2	15
267	Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9032-9032	2.2	14
266	A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9043-9043	2.2	1
265	First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9046-9046	2.2	10
264	BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9055-9055	2.2	24
263	A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9070-9070	2.2	19
262	Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20501-e20501	2.2	5
261	First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS2597-TPS2597	2.2	4
260	Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. <i>Oncotarget</i> , 2016 , 7, 13797-809	3.3	5
259	Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). <i>Oncotarget</i> , 2016 , 7, 36311-36320	3.3	36
258	Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: clinical implications of the LUX-Lung 7 study. <i>Annals of Translational Medicine</i> , 2016 , 4, 476	3.2	1
257	Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. <i>Journal of Pathology and Translational Medicine</i> , 2016 , 50, 258-63	2.9	34
256	Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial. <i>Cancer Research and Treatment</i> , 2016 , 48, 458-64	5.2	1
255	Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2016 , 48, 527-36	5.2	90
254	East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL). <i>Cancer Research and Treatment</i> , 2016 , 48, 1177-1186	5.2	13

253	Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e14118-e14118 ²		
252	Pattern and dynamics of recurrence after induction chemoradiotherapy (CCRT) followed by surgery (Trimodality Treatment) in stage IIIA(N2) NSCLC: The impact of response to preoperative CCRT on recurrence.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20030-e20030	2.2	
251	Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK+) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and -3.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20520-e20520	2.2	
250	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). <i>Oncotarget</i> , 2016 , 7, 6984-93	3.3	115
249	The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. <i>Journal of Thoracic Disease</i> , 2016 , 8, 3175-3186	2.6	3
248	The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 14803-13	3.3	37
247	Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study. <i>Cancer</i> , 2016 , 122, 3024-31	6.4	56
246	Fate of patients with nasopharyngeal cancer who developed distant metastasis as first failure after definitive radiation therapy. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E293-9	4.2	3
245	Vertical Magnetic Separation of Circulating Tumor Cells for Somatic Genomic-Alteration Analysis in Lung Cancer Patients. <i>Scientific Reports</i> , 2016 , 6, 37392	4.9	18
244	Efficacy and safety of dovitinib in pretreated advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase II study. <i>Journal of Thoracic Oncology</i> , 2016 , 11, S16	8.9	2
243	Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria. <i>Lung Cancer</i> , 2016 , 96, 48-51	5.9	4
242	AZD9291 overcomes T790M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells. <i>Investigational New Drugs</i> , 2016 , 34, 407-15	4.3	11
241	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology</i> , 2016 , 17, 577-89	21.7	691
240	Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease. <i>Lung Cancer</i> , 2016 , 96, 56-62	5.9	26
239	A Randomized Phase 2 Study Comparing the Combination of Ficlatazumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1736-44	8.9	36
238	Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease?. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 2202-2207 ³	8.9	3
237	Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer. <i>World Neurosurgery</i> , 2016 , 95, 399-405	2.1	5
236	BYL719, a selective inhibitor of phosphoinositide 3-Kinase β , enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer. <i>Investigational New Drugs</i> , 2015 , 33, 12-21	4.3	18

235	Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2450-6	2.2	55
234	Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy. <i>Clinical Lung Cancer</i> , 2015 , 16, 228-36	4.9	20
233	Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients. <i>Pharmacogenomics</i> , 2015 , 16, 383-91	2.6	6
232	EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 438-45	8.9	115
231	Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 331-7	8.9	116
230	Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2660-6	2.2	170
229	Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. <i>Lung Cancer</i> , 2015 , 90, 261-6	5.9	4
228	Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2015 , 125, 331-8	4.8	18
227	Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series. <i>Head and Neck</i> , 2015 , 37, E66-9	4.2	8
226	Low-density lipoprotein-mimicking nanoparticles for tumor-targeted theranostic applications. <i>Small</i> , 2015 , 11, 222-31	11	20
225	The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 903-9	8.9	26
224	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. <i>Oncotarget</i> , 2015 , 6, 40360-3	2.3	77
223	Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. <i>PLoS Genetics</i> , 2015 , 11, e1005467	6	86
222	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. <i>Oncotarget</i> , 2015 , 6, 28211-22	3.3	48
221	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 763-74	21.7	329
220	Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 77-85	3.5	10
219	A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 1229-36	3.5	5
218	A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1800-6	8.9	23

217	Tumor-targeted delivery of paclitaxel using low density lipoprotein-mimetic solid lipid nanoparticles. <i>Molecular Pharmaceutics</i> , 2015 , 12, 1230-41	5.6	40
216	Imaging: Low-Density Lipoprotein-Mimicking Nanoparticles for Tumor-Targeted Theranostic Applications (Small 2/2015). <i>Small</i> , 2015 , 11, 146-146	11	2
215	Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea. <i>Lung Cancer</i> , 2015 , 87, 148-54	5.9	59
214	Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8010-8010	2.2	67
213	A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8041-8041	2.2	1
212	Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8084-8084	2.2	25
211	A phase Ib/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8086-8086	2.2	1
210	The NEXT-2 (Next Generation Personalized Tx with Plasma DNA Genomics Trial-2 in Refractory Solid Tumors: cfDNA-Based Umbrella Trial, an interim analysis).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e12540-e12540	2.2	1
209	The prevalence and prognostic relevance of PD-L1 expression in patients with HPV-negative and HPV-positive oropharyngeal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14003-e14003	2.2	1
208	Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. <i>Oncotarget</i> , 2015 , 6, 30929-38	3.3	9
207	The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , 2015 , 6, 33358-68	3.3	21
206	NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. <i>Oncotarget</i> , 2015 , 6, 39028-35	3.3	46
205	Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2015 , 6, 44971-84	3.3	10
204	Prognostic value of volume-based positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. <i>Clinical and Experimental Otorhinolaryngology</i> , 2015 , 8, 142-8	3.4	21
203	The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. <i>Korean Journal of Internal Medicine</i> , 2015 , 30, 88-95	2.5	9
202	Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy. <i>Cancer Research and Treatment</i> , 2015 , 47, 871-8	5.2	17
201	Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015 , 47, 645-52	5.2	5
200	Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22241-e22241	2.2	

199	Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8078-8078	2.2	3
198	Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy. <i>Annals of Surgical Oncology</i> , 2014 , 21, 2083-90	3.1	21
197	Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. <i>Journal of Clinical Oncology</i> , 2014 , 32, 121-8	2.2	140
196	Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology</i> , 2014 , 15, 1254-62	21.7	71
195	First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. <i>European Journal of Cancer</i> , 2014 , 50, 2219-30	7.5	29
194	Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 1063-70	3.5	16
193	Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 1217-25	3.5	25
192	Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. <i>Cancer Imaging</i> , 2014 , 14, 2	5.6	22
191	A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin. <i>Lung Cancer</i> , 2014 , 84, 51-5	5.9	24
190	Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. <i>Lancet</i> , 2014 , 384, 665-73	40	799
189	High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma. <i>Journal of Translational Medicine</i> , 2014 , 12, 299	8.5	37
188	Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR. <i>Oncologist</i> , 2014 , 19, 702-3	5.7	10
187	Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2059-66	2.2	105
186	Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1523-31	8.9	15
185	Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 506-11	8.9	38
184	Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2014 , 83, 259-64	5.9	26
183	Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 50-8	8.8	90
182	Abstract 1526: Integrative and comparative genomic analysis of East-Asian lung squamous cell carcinomas 2014 ,		2

181	A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CCheIN).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7500-7500	2.2	3
180	A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8000-8000	2.2	23
179	Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8011-8011	2.2	33
178	Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatinib plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and gefitinib/erlotinib (E/E).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8012-8012	2.2	16
177	Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8044-8044	2.2	8
176	A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8051-8051	2.2	20
175	REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8006-8006	2.2	5
174	Phase I/II multicenter, randomized, open-label trial of the c-Met inhibitor MSC2156119J and gefitinib versus chemotherapy as second-line treatment in patients with MET-positive (MET+), locally advanced, or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor mutation (EGFRm) and progression on gefitinib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TP38121-TP38121	2.2	
173	The presence of ALK translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e17048-e17048	2.2	
172	Comparison of concurrent chemoradiation therapy with 3-weekly versus weekly cisplatin in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II noninferiority trial (KCSG-HN10-02).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6023-6023	2.2	
171	A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of esophagus.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4083-4083	2.2	
170	Randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8037-8037	2.2	
169	Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. <i>Head and Neck</i> , 2013 , 35, 15-22	4.2	95
168	Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute. <i>Medical Oncology</i> , 2013 , 30, 479	3.7	12
167	Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 1005-13	8.8	45
166	Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery. <i>Lung Cancer</i> , 2013 , 79, 300-6	5.9	19
165	The effect of N/P ratio on the in vitro and in vivo interaction properties of PEGylated poly[2-(dimethylamino)ethyl methacrylate]-based siRNA complexes. <i>Macromolecular Bioscience</i> , 2013 , 13, 1059-71	5.5	42
164	Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. <i>Journal of Molecular Diagnostics</i> , 2013 , 15, 51-61	5.1	57

163	Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2013 , 79, 40-5	5.9	27
162	Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging system. <i>Lung Cancer</i> , 2013 , 81, 65-70	5.9	17
161	Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2013 , 82, 294-8	5.9	96
160	A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. <i>Lung Cancer</i> , 2013 , 82, 455-60	5.9	28
159	The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2013 , 81, 231-5	5.9	14
158	Rapid detection of exon 2-deleted AIMP2 mutation as a potential biomarker for lung cancer by molecular beacons. <i>Biosensors and Bioelectronics</i> , 2013 , 46, 142-9	11.8	11
157	Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. <i>Genomics</i> , 2013 , 102, 157-62	4.3	40
156	A new KIT gene mutation in thymic cancer and a promising response to imatinib. <i>Journal of Thoracic Oncology</i> , 2013 , 8, e91-2	8.9	3
155	Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 250-3	8.9	37
154	Ethnic differences in non-small-cell lung cancer treatment: the Asian perspective. <i>Lung Cancer Management</i> , 2013 , 2, 309-315	2.6	1
153	Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 185-91	8.9	124
152	A prospective phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 959-66	8.9	28
151	Abstract B25: Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686. 2013 ,		4
150	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8027-8027	2.2	17
149	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8028-8028	2.2	26
148	Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer. <i>PLoS ONE</i> , 2013 , 8, e64816	3.7	58
147	Tumor lysis syndrome in a solid tumor: a case report of a patient with invasive thymoma. <i>Cancer Research and Treatment</i> , 2013 , 45, 343-8	5.2	4
146	Roles of cMET/ErbB3 activation and overexpression in the development of resistance to EGFR inhibitors in NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11113-11113	2.2	

145	Comparison of clinical outcome between gefitinib and erlotinib treatment in patients with non-small cell lung cancer harboring an epidermal growth factor receptor exon 19 or exon 21 mutations.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e19051-e19051	2.2	
144	High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients. <i>Anticancer Research</i> , 2013 , 33, 5127-33	2.3	1
143	Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. <i>Investigational New Drugs</i> , 2012 , 30, 368-75	4.3	16
142	The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. <i>Human Genetics</i> , 2012 , 131, 365-72	6.3	41
141	A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. <i>Journal of Thoracic Oncology</i> , 2012 , 7, e36-e38	8.9	77
140	Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 315-20	3.5	12
139	The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 784-91	6.1	130
138	EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. <i>Lancet Oncology, The</i> , 2012 , 13, 33-42	21.7	459
137	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. <i>Lancet Oncology, The</i> , 2012 , 13, 528-38	21.7	777
136	Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes. <i>Academic Radiology</i> , 2012 , 19, 440-5	4.3	11
135	Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). <i>Journal of Clinical Oncology</i> , 2012 , 30, 1114-21	2.2	205
134	International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2829-36	2.2	158
133	A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01). <i>European Journal of Cancer</i> , 2012 , 48, 3198-204	7.5	17
132	Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. <i>Lung Cancer</i> , 2012 , 75, 82-8	5.9	83
131	ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis. <i>Lung Cancer</i> , 2012 , 76, 253-4	5.9	18
130	Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study. <i>Lung Cancer</i> , 2012 , 77, 339-45	5.9	27
129	Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?. <i>Lung Cancer</i> , 2012 , 77, 365-70	5.9	96
128	First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1122-8	2.2	607

127	High dose involved field radiation therapy as salvage for loco-regional recurrence of non-small cell lung cancer. <i>Yonsei Medical Journal</i> , 2012 , 53, 1120-7	3	15
126	Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response?. <i>Korean Journal of Radiology</i> , 2012 , 13, 702-10	6.9	49
125	Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. <i>Cancer</i> , 2012 , 118, 6234-42	6.4	72
124	Reappraisal of KIT mutation in adenoid cystic carcinomas of the salivary gland. <i>Journal of Oral Pathology and Medicine</i> , 2012 , 41, 415-23	3.3	5
123	Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3337-44	2.2	214
122	Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. <i>Radiology</i> , 2012 , 265, 939-48	20.5	89
121	The effectiveness of maintenance pharmacotherapies for non-small cell lung cancer. <i>Clinical Medicine Insights: Oncology</i> , 2012 , 6, 253-62	1.8	1
120	Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): Asian subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7549-7549	2.2	1
119	Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator choice chemotherapy following progression on afatinib monotherapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7557-7557	2.2	11
118	EGFR status and daily dose: Effect on tumor growth inhibition in cancer patients treated with dacomitinib (PF-00299804).. <i>Journal of Clinical Oncology</i> , 2012 , 30, e18093-e18093	2.2	3
117	ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS7614-TPS7614	2.2	7
116	High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. <i>Histology and Histopathology</i> , 2012 , 27, 197-207	1.4	110
115	A prospective, phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7104-7104	2.2	
114	Metabolic response evaluated by 18F-FDG PET/CT as a potential tool in identifying subgroup of patients with advanced non-small cell lung cancer for immediate maintenance treatment after first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e18148-e18148	2.2	
113	Comparison of clinical outcomes between concurrent chemoradiotherapy followed by adjuvant chemotherapy and concurrent chemoradiotherapy alone for patients associated with locally advanced nasopharyngeal carcinoma: A retrospective analysis of single center experience.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e16003-e16003	2.2	
112	Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. <i>Lung Cancer</i> , 2011 , 71, 89-93	5.9	63
111	New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy. <i>Lung Cancer</i> , 2011 , 73, 63-9	5.9	43
110	INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. <i>BMC Cancer</i> , 2011 , 11, 430	4.8	59

109	Outcomes of mediastinoscopy and surgery with or without neoadjuvant therapy in patients with non-small cell lung cancer who are N2 negative on positron emission tomography and computed tomography. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 336-42	8.9	20
108	Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1392-9	8.9	87
107	Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2011 , 47, 714-9	4.4	15
106	Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit. <i>Supportive Care in Cancer</i> , 2011 , 19, 491-5	3.9	35
105	The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011 , 137, 687-94	4.9	25
104	Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011 , 137, 1203-11	4.9	39
103	Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 531-8	3.5	12
102	Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1099-109	3.5	72
101	Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors. <i>Cancer</i> , 2011 , 117, 143-51	6.4	27
100	Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 80, 655-60	4	32
99	Influence of nano-carrier architecture on in vitro siRNA delivery performance and in vivo biodistribution: polyplexes vs micelleplexes. <i>ACS Nano</i> , 2011 , 5, 3493-505	16.7	97
98	Dry pleural dissemination in non-small cell lung cancer: prognostic and diagnostic implications. <i>Radiology</i> , 2011 , 260, 568-74	20.5	17
97	A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. <i>Oncology</i> , 2011 , 80, 175-80	3.6	24
96	Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria. <i>Korean Journal of Radiology</i> , 2010 , 11, 618-26	6.9	19
95	Lung cancer working group report. <i>Japanese Journal of Clinical Oncology</i> , 2010 , 40 Suppl 1, i7-12	2.8	17
94	Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment. <i>Oncology</i> , 2010 , 79, 78-84	3.6	11
93	Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?. <i>Lung Cancer</i> , 2010 , 68, 258-63	5.9	24
92	A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2010 , 68, 420-6	5.9	50

91	Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2010 , 69, 105-9	5.9	20
90	Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy. <i>Lung Cancer</i> , 2010 , 69, 330-6	5.9	58
89	The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010 , 69, 323-9	5.9	50
88	Stepwise evolution from a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: an observation for more than 10 years. <i>Lung Cancer</i> , 2010 , 69, 123-6	5.9	54
87	Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons. <i>Journal of Molecular Diagnostics</i> , 2010 , 12, 644-52	5.1	14
86	Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. <i>Clinical Cancer Research</i> , 2010 , 16, 1307-14	12.9	155
85	Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naïve patients with extensive-disease small cell lung cancer. <i>Cancer</i> , 2010 , 116, 132-6	6.4	13
84	Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 688-95	8.9	36
83	Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1185-96	8.9	47
82	Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 540-5	8.9	27
81	Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 369-75	8.9	35
80	Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1609-15	8.9	29
79	Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA). <i>Medical Oncology</i> , 2010 , 27, 1234-8	3.7	16
78	Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. <i>Cancer</i> , 2010 , 116, 676-85	6.4	32
77	Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. <i>Cancer</i> , 2010 , 116, 3025-33	6.4	31
76	Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 78, 507-12	4	17
75	Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras. <i>Oncology</i> , 2009 , 76, 239-46	3.6	15
74	Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 5861-8	12.9	166

73	Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. <i>International Journal of Cancer</i> , 2009 , 124, 1457-62	7.5	58
72	Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. <i>Cancer</i> , 2009 , 115, 1518-30	6.4	18
71	Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009 , 118, 89-97	4.4	32
70	The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma. <i>Medical Oncology</i> , 2009 , 26, 287-91	3.7	41
69	Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified". <i>Annals of Hematology</i> , 2009 , 88, 111-9	3	27
68	Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 917-24	3.5	3
67	Protein profiling in human sera for identification of potential lung cancer biomarkers using antibody microarray. <i>Proteomics</i> , 2009 , 9, 5544-52	4.8	20
66	L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors. <i>Apmis</i> , 2009 , 117, 140-6	3.4	12
65	Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer. <i>Apmis</i> , 2009 , 117, 861-9	3.4	14
64	Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. <i>European Journal of Cancer</i> , 2009 , 45, 2298-303	7.5	37
63	Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial. <i>Lung Cancer</i> , 2009 , 66, 338-43	5.9	14
62	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. <i>Lancet, The</i> , 2009 , 373, 1525-31	40	1138
61	Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 809-15	8.9	127
60	Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 1136-43	8.9	23
59	Modest anti-cancer activity of a bile acid acylated heparin derivative in a PC14PE6 induced orthotopic lung cancer model. <i>Cancer Research and Treatment</i> , 2009 , 41, 80-6	5.2	2
58	Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3543-51	2.2	2607
57	Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?. <i>Clinical Cancer Research</i> , 2008 , 14, 3860-6	12.9	47
56	Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008 , 49, 88-94	1.9	19

55	FDG PET/CT and mediastinal nodal metastasis detection in stage T1 non-small cell lung cancer: prognostic implications. <i>Korean Journal of Radiology</i> , 2008 , 9, 481-9	6.9	9
54	Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. <i>Investigational New Drugs</i> , 2008 , 26, 387-92	4.3	17
53	A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 77-84	2.5	34
52	Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma. <i>Medical Oncology</i> , 2008 , 25, 447-50	3.7	5
51	ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. <i>Cancer</i> , 2008 , 113, 1379-86	6.4	63
50	Analyses on prognostic factors following tri-modality therapy for stage IIIa non-small cell lung cancer. <i>Lung Cancer</i> , 2007 , 55, 329-36	5.9	19
49	Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer. <i>Lung Cancer</i> , 2007 , 58, 116-22	5.9	18
48	Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. <i>American Journal of Hematology</i> , 2007 , 82, 446-52	7.1	39
47	Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. <i>Cancer</i> , 2007 , 109, 1561-9	6.4	113
46	Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging. <i>Biomaterials</i> , 2007 , 28, 5555-61	15.6	83
45	Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. <i>Leukemia Research</i> , 2007 , 31, 359-64	2.7	31
44	What is stage II in high-grade primary gastric lymphoma? How to define the range of "localized disease". <i>Leukemia Research</i> , 2007 , 31, 1039-43	2.7	1
43	Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. <i>Clinical Immunology</i> , 2007 , 125, 257-67	9	59
42	A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 60, 489-94	3.5	18
41	Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 17-21	3.5	19
40	Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. <i>Clinical Cancer Research</i> , 2007 , 13, 3250-4	12.9	37
39	Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5233-9	2.2	150
38	Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007 , 48, 716-22	1.9	25

37	P2-328: Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007 , 2, S851	8.9	67
36	Clinical evaluation of incadronate in Korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study. <i>Current Therapeutic Research</i> , 2007 , 68, 193-204	2.4	1
35	Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study. <i>Cancer Letters</i> , 2007 , 258, 90-7	9.9	18
34	Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract. <i>Neoplasia</i> , 2007 , 9, 18-22	6.4	28
33	The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. <i>Blood</i> , 2007 , 110, 972-8	2.2	245
32	Postremission therapy for acute myeloid leukemia in the first remission. <i>Leukemia and Lymphoma</i> , 2007 , 48, 937-43	1.9	4
31	C3-06: ERCC1 expression as a predictive marker in stage IIIA, N2 positive non-small cell lung cancer patients treated with neoadjuvant concurrent chemoradiotherapy followed by surgery. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S367	8.9	2
30	Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia. <i>Annals of Hematology</i> , 2006 , 85, 285-90	3	17
29	Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. <i>Annals of Hematology</i> , 2006 , 85, 781-6	3	37
28	Prognostic factor analysis and proposed prognostic model for conventional treatment of high-grade primary gastric lymphoma. <i>European Journal of Haematology</i> , 2006 , 77, 304-8	3.8	8
27	Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4028-9	2.2	22
26	CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1253-9	1.9	14
25	High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: a clinicopathologic study of 18 cases in the Korean population. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2128-31	1.9	12
24	Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience. <i>Lung Cancer</i> , 2006 , 52, 75-81	5.9	9
23	Is trimodality approach better than bimodality in stage IIIA, N2 positive non-small cell lung cancer?. <i>Lung Cancer</i> , 2006 , 53, 323-30	5.9	21
22	Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 612-8	2.2	457
21	A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. <i>Current Medical Research and Opinion</i> , 2006 , 22, 561-73	2.5	77
20	Pulmonary complications after hematopoietic stem cell transplantation. <i>Journal of Korean Medical Science</i> , 2006 , 21, 406-11	4.7	23

19	Prognosis of non-small cell lung cancer with synchronous brain metastases treated with gamma knife radiosurgery. <i>Journal of Korean Medical Science</i> , 2006 , 21, 527-32	4.7	13
18	Primary gastric lymphoma of T-cell origin: clinicopathologic features and treatment outcome. <i>Leukemia Research</i> , 2006 , 30, 1253-8	2.7	9
17	Preoperative concurrent radiochemotherapy and surgery for stage IIIA non-small cell lung cancer. <i>Journal of Korean Medical Science</i> , 2006 , 21, 229-35	4.7	3
16	Mouse orthotopic lung cancer model induced by PC14PE6. <i>Cancer Research and Treatment</i> , 2006 , 38, 234-9	5.2	13
15	Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. <i>European Journal of Cancer</i> , 2005 , 41, 1402-8	7.5	136
14	Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. <i>Annals of Thoracic Surgery</i> , 2005 , 80, 1170-5	2.7	49
13	Influential factors for the collection of peripheral blood stem cells and engraftment in acute myeloid leukemia patients in first complete remission. <i>International Journal of Hematology</i> , 2005 , 81, 258-63	2.3	6
12	Nongastric Marginal Zone B-Cell Lymphoma: Analysis of 247 Cases - Clinical Presentation and Treatment Outcomes of Nongastric Marginal Zone B-Cell Lymphoma.. <i>Blood</i> , 2005 , 106, 1491-1491	2.2	
11	Intestinal lymphoma: exploration of the prognostic factors and the optimal treatment. <i>Leukemia and Lymphoma</i> , 2004 , 45, 339-44	1.9	39
10	Primary pulmonary non-Hodgkin's lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 2004 , 34, 510-4	2.8	83
9	Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 4383-8	12.9	71
8	Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 477-80	2.7	38
7	A Randomized Trial of Short-Course Preemptive Ganciclovir Compared with Conventional Ganciclovir Therapy To Prevent Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004 , 104, 3162-3162	2.2	1
6	A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers. <i>Lung Cancer</i> , 2003 , 42, 227-35	5.9	17
5	Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 52, 75-80	4	39
4	Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. <i>Investigational New Drugs</i> , 2001 , 19, 81-3	4.3	113
3	Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. <i>Human Gene Therapy</i> , 2001 , 12, 671-84	4.8	108
2	Mechanistic aspects of green tea as a cancer preventive: effect of components on human stomach cancer cell lines. <i>Japanese Journal of Cancer Research</i> , 1999 , 90, 733-9		120

- 1 Fractionated stereotactic radiation therapy for locally recurrent nasopharynx cancer: report of three cases. *Head and Neck*, **1999**, 21, 338-45 4.2 11